ArticleDiscover oncology2025
Prognostic role of eIF2α protein in metastatic renal cell cancer patients.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundOne of the major dilemmas in the treatment of renal cell carcinoma (RCC) is the resistance to therapy that leads to a state of unresponsiveness, which is observed after a certain period. Among the potential causes of this, the impact of autophagy activation and the resulting endoplasmic reticulum (ER) stress due to the accumulation of misfolded or unfolded proteins has not been previously investigated.
methodsPatients treated in medical oncology clinics of a total of 3 centers between January 2011 and May 2022 were included. In the pathology preparations of a total of 83 patients diagnosed with metastatic RCC, we examined the effects of autophagy activation induced by mTOR inhibition through the analysis of LC3 and Beclin1 molecules, the differentiation from classical apoptosis pathways with the Bcl-2 level, the hypoxic condition with the HIF-1α level, and ER stress with the eukaryotic initiation factor 2α (eIF2α) level.
resultsİn our study, found no significant effects of LC3 (p = 0.298), Beclin1 (p = 0.287), Bcl-2 (p = 0.435), and HIF-1α (p = 0.179) levels on either progression-free survival or overall survival. However, eIF2α (p = 0.017) was found to be a significantly decisive factor.
conclusionBased on these results, we suggest that eIF2α may serve as a novel biomarker to predict survival and treatment response in metastatic RCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.